H.C. Wainwright raised the firm’s price target on Nektar (NKTR) to $120 from $6.50 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today?
- Nektar jumps 130% to $21.90 after atopic dermatitis study success
- Nektar Therapeutics Announces Positive Phase 2b Trial Results
- Nektar’s rezpegaldesleukin meets endpoints in Phase 2b atopic dermatitis trial
- Closing Bell Movers: Futures up on Iran/Israel truce, KB Home slips on outlook